[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356515-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356515-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-hybrid-pkpd-agent-based-model-of-the-tumour-immune-interaction-effects-of-anti-cancer-combination-therapy","A hybrid PKPD agent-based model of the tumour immune interaction - effects of anti-cancer combination therapy","","A three-dimensional hybrid multiscale agent-based ODE-PDE model is developed to capture tumour–immune interactions alongside cell-cycle phases, oxygen and drug diffusion, chemotherapy pharmacodynamics, targeted therapies, immunotherapy, radiotherapy, and systemic pharmacological exposure linked to pharmacokinetic modelling. The model aims to explain spatial–temporal dynamics among cancer cells, immune cells, and therapy molecular components within the tumour microenvironment. Combination therapies are used to analyse mechanistic positive and negative synergies, with emphasis on temporal sequencing and simultaneous modelling of multiple system components.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-hybrid-pkpd-agent-based-model-of-the-tumour-immune-interaction-effects-of-anti-cancer-combination-therapy/356515/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-hybrid-pkpd-agent-based-model-of-the-tumour-immune-interaction-effects-of-anti-cancer-combination-therapy/356515.png","ImageObject",300,407,{"name":42,"@type":43},"Mia  ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What modelling framework is proposed for tumour–immune interactions?","Question",{"text":63,"@type":64},"A three-dimensional hybrid multiscale agent-based ODE-PDE model is used, combining tumour–immune interaction dynamics with cell-cycle phases, oxygen and drug diffusion, and pharmacodynamic effects tied to pharmacokinetic exposure.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the model support analysis of combination therapy effects?",{"text":68,"@type":64},"It investigates spatial–temporal interactions in the tumour microenvironment under combination therapies to explore mechanistic positive and negative synergies, including how temporal sequencing changes outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is temporal sequencing important in combination therapy modelling?",{"text":72,"@type":64},"Because combination therapy requires simultaneous modelling of multiple system components, the document highlights temporal sequencing as a key factor driving interaction dynamics and therapeutic effect.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356515,1790220127,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of Pharmacokinetics and Pharmacodynamics (2026) 53:16  \n[https://doi.org/10.1007/s10928-026-10021-2](https://doi.org/10.1007/s10928-026-10021-2)  \nORIGINAL PAPER  \nA hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy  \nVan Thuy Truong1,2 · Grant Lythe2 · Paolo Vicini3 · James W. T. Yates4 · Vincent F. S. Dubois1  \nReceived: 4 September 2025 / Accepted: 10 January 2026 / Published online: 24 March 2026 © The Author(s) 2026  \nAbstract  \nWe have developed a three dimensional hybrid multiscale agent-based ODE PDE model including tumour immune interaction, cell cycle phases, oxygen and drug diffusion dynamics, the pharmacodynamics of chemotherapy, targeted therapies, immunotherapy, radiotherapy and the respective systemic exposure levels of pharmacological treatments (described by pharmacokinetic modelling) . The aim of this model is to support understanding of the spatial-temporal dynamic interactions between cancer cells, the relevant immune cells, and targeted therapies’ molecular moieties, which interact simultaneously in the tumour microenvironment. This interaction is further investigated in the context of combination therapies, thus making some inroads in the mechanistic understanding of positive and negative synergies when multiple therapies are administered. This work addresses the role of temporal sequencing in combination therapies, which requires the simultaneous modelling of multiple system components.  \nKeywords Agent-based modelling · Cancer · Tutorial · Ordinary differential equation · Partial differential equation · Tumor microenvironment · Chemotherapy · Radiotherapy · DNA damage response inhibitor · PD1 antibody · Pharmacometrics · Pharmacokinetics · Pharmacodynamics · Quantitative systems pharmacology  \nIntroduction  \nTumour survival and escape depend on various factors, including the immune response, concentration gradients (for example, those of oxygen and drug in the tumour micro environment (TME)), and on tumour cell characteristics (such as the location, cell-cycle phase and PDL1 expression status) . In healthy tissue, the programmed cell death protein-1 (PD1) and its ligand PDL1 prevent  \n􀀍 Van Thuy Truong [vn.thuy.truong@gmail.com](vn.thuy.truong@gmail.com)  \n1 Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge  \nCB21 6GH, UK  \n2 Department of Applied Mathematics, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, United Kingdom  \n3 Confo Therapeutics, Technologiepark 94, Ghent (Zwijnaarde) 9052, Belgium  \n4 DMPK, Preclinical Sciences, RD Research, GSK, Gunnels Wood Road, Stevenage, Hertfordshire  \nSG1 2NY, United Kingdom  \nexcessive immune activity and serve as an immune checkpoint pathway to maintain ‘self’ tolerance. Under prolonged immune stress, PDL1 expression can be induced on cancer cells and other cells in the TME, producing an immunosuppressive environment [1] . Cell death due to radiotherapy can be induced by a combination of direct radiation-mediated cytotoxicity and the stimulation of an antitumor immune response, also known as the abscopal effect [2, 3] . Immune effector cells and suppressor cells can be subject to radiation-mediated cytotoxicity but more can be attracted by radiotherapy-induced cancer cell death [4] . In addition, radiotherapy-induced cancer cell death causes PDL1 overexpression [5] . Furthermore, the efficacy of radiotherapy depends on the oxygenation status of the tumour cells as hypoxic cells are less radiosensitive. Cell-cycle regulation also plays an important role. For example, cells in the G2-M phase are more sensitive to radiation than those in the G1 phase. Radiation can activate cell repair mechanisms such as the intracellular p53 and p21 pathways which results in cell cycle delay, accumulation in the G1 or G2 phase, and synchronisation [6] . DNA damage response inhibitors counteract these repair mec","cbCaidt5Yj88j5QV","https://ap.wps.com/l/cbCaidt5Yj88j5QV","pdf",7341676,17,"English","# Abstract\n# Introduction\n## Immune checkpoint and tumour microenvironment\n## Radiotherapy mechanisms and cell-cycle effects\n## DNA damage response inhibitors and chemotherapy interactions\n## PD1/PDL1 blockade and rationale for combination therapies\n## Need for PK/PD modelling with spatial and temporal dynamics","[{\"question\":\"What modelling framework is proposed for tumour–immune interactions?\",\"answer\":\"A three-dimensional hybrid multiscale agent-based ODE-PDE model is used, combining tumour–immune interaction dynamics with cell-cycle phases, oxygen and drug diffusion, and pharmacodynamic effects tied to pharmacokinetic exposure.\"},{\"question\":\"How does the model support analysis of combination therapy effects?\",\"answer\":\"It investigates spatial–temporal interactions in the tumour microenvironment under combination therapies to explore mechanistic positive and negative synergies, including how temporal sequencing changes outcomes.\"},{\"question\":\"Why is temporal sequencing important in combination therapy modelling?\",\"answer\":\"Because combination therapy requires simultaneous modelling of multiple system components, the document highlights temporal sequencing as a key factor driving interaction dynamics and therapeutic effect.\"}]","A hybrid PKPD agent-based model of the tumour immune interaction - effects of anti-cancer combination therapy | PDF",1790125740,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d45fea9fd4024a33268466a522d9605.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08427fbd05d5128e3fbf837fbec32466.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b9f11249691a73d9b6ab316308a367e.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3321d1b821cadabdaa1260d9dbb62537.webp",980,1301]